Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Thursday broker round-up

Thu, 12th Dec 2019 13:38

(Sharecast News) - Synthomer: JP Morgan upgrades to neutral with a target price of 300p.

CRH: UBS reiterates buy with a target price of 3,300p.

Anglo American: UBS reiterates sell with a target price of 1,800p.

Derwent London: JP Morgan reiterates underweight with a target price of 3,500p.

Ashtead: Liberum Capital reiterates buy with a target price of 2,616p.

easyJet: Deutsche Bank reiterates hold with a target price of 1,540p.

AstraZeneca: Deutsche Bank reiterates buy with a target price of 8,400p.

Fuller Smith & Turner: Peel Hunt upgrades to add with a target price of 1,050p.

Homeserve: HSBC reiterates reduce with a target price of 1,090p.

Related Shares

More News

3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsort...

3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out...

2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...

2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood canc...